Liposomal formulation of chondroitin sulfate enhances its antioxidant and anti-inflammatory potential in L929 fibroblast cell line

Journal of Liposome Research

Volumn 23, Issue 2, 2013, Pages 145-153

  Craciunescu, Oana ^a   Moldovan, Lucia ^a   Moisei, Magdalena ^b   Trif, Mihaela ^b  

^a National Institute of R and D for Biological Sciences   (Romania)

^b INSTITUTE OF BIOCHEMISTRY OF THE ROMANIAN ACADEMY   (Romania)

Author keywords

Cytokines; Cytotoxicity; Liposome particle size; Morphology; Oxidative damage

Indexed keywords

CHONDROITIN SULFATE; HYDROGEN PEROXIDE; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY TEST; DRUG FORMULATION; ENZYME ACTIVITY; FIBROBLAST CULTURE; HYDRATION; IN VITRO STUDY; LIGHT SCATTERING; LIPOSOMAL DELIVERY; LOCAL THERAPY; MOUSE; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; ULTRASOUND; ZETA POTENTIAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CELL LINE; CHONDROITIN SULFATES; LIPOSOMES; MICE; MICROSCOPY, ELECTRON, TRANSMISSION;

EID: 84878449161     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.3109/08982104.2013.770016     Document Type: Article

References (57)

1. Anderson R, Franch A, Castell M, et al. (2010). Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis. Arthritis Res Ther 12:R147-61.
2. Bonnet CS, Walsh DA. (2005). Osteoarthritis, angiogenesis and inflammation. Rheumatology (Oxford) 44:7-16. (Pubitemid 40136474)
3. Burt H, Tsallas A, Gilchrist S, Liang L. (2009). Intra-articular drug delivery systems: overcoming the shortcomings of joint disease therapy. Expert Opin Drug Deliv 6:17-26.
4. Butoescu N, Jordan O, Doelker E. (2009). Intra-articular drug delivery systems for the treatment of rheumatic diseases: a review of the factors influencing their performance. Eur J Pharm Biopharm 73:205-18.
5. Campo G.M, Avenoso A, Campo S, et al. (2003). Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats. Arthritis Res Ther 5:R122-31.
6. Chen MP, Yang SH., Chou CH, et al. (2010). The chondroprotective effects of ferulic acid on hydrogen peroxide-stimulated chondrocytes: inhibition of hydrogen peroxide-induced pro-inflammatory cytokines and metalloproteinase gene expression at the mRNA level. Inflamm Res 59:587-95.
7. Clegg DO, Reda DJ, Harris CL, et al. (2006). Glucosamine and chondroitin sulfate and the two in combination for painful knee osteoarthritis. New Engl J Med 354:795-808. (Pubitemid 43290918)
8. Costin GE, Trif M, Nichita N, et al. (2002). pH-sensitive liposomes are efficient carriers for endoplasmic reticulum targeted drugs in mouse melanoma cells. Biochem Biophys Res Commun 293:918-23. (Pubitemid 34694128)
9. Craciunescu O, Constantin D, Gaspar A, et al. (2012). Evaluation of antioxidant and cytoprotective activities of Arnica montana L. and Artemisia absinthium L. ethanolic extracts. Chem Cent J 6:97-107.
10. Deberg M, Labasse A, Christgau S, et al. (2005). New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 13:258-65. (Pubitemid 40277284)
11. Edwards SH, Cake MA, Spoelstra G, Read RA. (2007). Biodistribution and clearance of intra-articular liposomes in a large animal model using a radiographic marker. J Liposome Res 17:249-62.
12. French MM, Rose S, Canseco J, Athanasiou KA. (2004). Chondrogenic differentiation of adult dermal fibroblasts. Ann Biomed Eng 32:50-6.
13. Furuzawa-Carballeda J, Munoz-Chable OA, Barrios-Payan J, Hernandez-Pando R. (2009). Effect of polymerized-type I collagen in knee osteoarthritis. I. In vitro studies. Eur J Clin Invest 39:591-7.
14. Gerwin N, Hops C, Lucke A. (2006). Intraarticular drug delivery in osteoarthritis. Adv Drug Deliv Rev 58:226-42.
15. Gomez-Barrena E, Lindroos L, Ceponis A, et al. (2006). Cartilage oligomeric matrix protein (COMP) is modified by intra-articular liposomal clodronate in an experimental model of arthritis. Clin Exp Rheumatol 24:622-8. (Pubitemid 46138792)
16. Goyal P, Goyal K, Vijaya KU, et al. (2005). Liposomal drug delivery systems-clinical applications. Acta Pharm 55:1-25. (Pubitemid 40562616)
17. Gutteridge J.M, Halliwell B. (1990). The measurement and mechanism of lipid peroxidation in biological systems. Trends Biochem Sci 15:129-35. (Pubitemid 20186835)
18. Henrotin Y, Kurz B, Aigner T. (2005). Oxygen and reactive oxygen species in cartilage degradation: friends or foes? Osteoarthritis Cartilage 13:643-54. (Pubitemid 41025117)
19. Higaki H, Murakami T, Nakanishi Y, et al. (1998). The lubricating ability of biomembrane models with dipalmitoyl phosphatidylcholine and gamma-globulin. Proc Inst Mech Eng [H] 212:337-46. (Pubitemid 128770002)
20. Huskisson EC. (2008). Glucosamine and chondroitin for osteoarthritis. J Int Med Res 36:1161-79.
21. Khan I.M, Gilbert SJ, Caterson B, et al. (2008). Oxidative stress induces expression of osteoarthritis markers procollagen IIA and 3B3(-) in adult bovine articular cartilage. Osteoarthritis Cartilage 16:698-707.
22. Kobo M, Ando K, Mimura T, et al. (2009). Chondroitin sulfate for the treatment of hip and knee osteoarthritis: current status and future trends. Life Sci 85:477-83.
23. Kurosaki T, Kitahara T, Fumoto S, et al. (2010). Chondroitin sulfate capsule system for efficient and secure gene delivery. J Pharm Pharmaceut Sci 13:351-61.
24. Lamari FN. (2008). The potential of chondroitin sulfate as a therapeutic agent. Connect Tissue Res 49:289-92.
25. Lavelle W, Lavelle ED, Lavelle L. (2007). Intra-articular injections. Anesthesiol Clin 25:853-62. (Pubitemid 350180666)
26. Lehner R, Wang X, Wolf M, Hunziker P. (2012). Designing switchable nanosystems for medical applications. J Control Release 161:307-16.
27. Leung BP, Conacher M, Hunter D, et al. (2002). A novel dendritic cell-induced model of erosive inflammatory arthritis: distinct roles for dendritic cells in T cell activation and induction of local inflammation. J Immunol 169:7071-7. (Pubitemid 36899295)
28. Li H, Zhao X, Ma Y, et al. (2009). Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release 133:238-44.
29. Lian T, Ho RJ. (2001). Trends and developments in liposome drug delivery systems. J Pharm Sci 90:667-80. (Pubitemid 32530443)
30. Lim JJ, Hammoudi TM, Bratt-Leal AM, et al. (2011). Development of nano-and micro-scale chondroitin sulfate particles for controlled growth factor delivery. Acta Biomater 7:986-95.
31. Loeser RF. (2011). Aging and osteoarthritis. Curr Opin Rheumatol 23:492-6.
32. Metselaar JM, Storm G. (2005). Liposomes in the treatment of inflammatory disorders. Expert Opin Drug Deliv 2:465-76. (Pubitemid 41683222)
33. Mitsopoulos P, Suntres ZE. (2011). Protective effects of liposomal N-acetylcysteine against paraquat-induced cytotoxicity and gene expression. J Toxicol 2011:808967.
34. Moldovan L, Buzgariu W, Zarnescu O, et al. (2003). In vitro biocom-patibility evaluation of some corneal biopolymers. Rom Biol Sci 1:23-34.
35. Monfort J, Pelletier JP, Garcia-Giralt N, Martel-Pelletier J. (2008). Biochemical basis of the effect of chondroitin sulphate on osteoarth-ritis articular tissues. Ann Rheum Dis 67:735-40. (Pubitemid 351829371)
36. Montella A, Manunta A, Espa E, et al. (1992). Human articular cartilage in osteoarthritis. I. The matrix. Transmission electron microscopic study. Ital J Anat Embryol 97:1-12.
37. Mossman T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays. J Immunol Methods 65:55-63.
38. Mountziaris PM, Kramer PR, Mikos AG. (2009). Emerging intra-articular drug delivery systems for the temporomandibular joint. Methods 47:134-40.
39. Mozafari MR. (2010). Nanoliposomes: preparation and analysis. Methods Mol Biol 605:29-50.
40. Muller RH, Mader K, Gohla S. (2000). Solid lipid nanoparticles for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 50:161-77. (Pubitemid 30326695)
41. Navarro-Sarabia F, Coronel P, Collantes E, et al. (2011). A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project. Ann Rheum Dis 70:1957-62.
42. New RRC. (1997). Preparation of liposomes. In: Rickwood D, Hames BD, eds. Liposomes: a practical approach. Oxford, New York, Tokyo: IRC Oxford, 33-110.
43. Peran M, Garcia MA, Lopez-Ruiz E, et al. (2012). Functionalized nanostructures with application in regenerative medicine. Int J Mol Sci 13:3847-86.
44. Perrie Y, Mohammed AUR, Vangala A, McNeil SE. (2007). Environmental scanning electron microscopy offers real-time morphological analysis of liposomes and niosomes. J Lipos Res 17:27-37. (Pubitemid 46631139)
45. Rainbow R, Ren W, Zeng L. (2012). Inflammation and joint tissue interactions in OA: implications for potential therapeutic approaches. Arthritis 2012:741582.
46. Reichenbach S, Sterchi R, Scherer M, et al. (2007). Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 146:580-90. (Pubitemid 351650539)
47. Samad A, Sultana Y, Aqil M. (2007). Liposomal drug delivery systems: an update review. Curr Drug Deliv 4:297-305. (Pubitemid 47554274)
48. Schwendener RA. (2007). Liposomes in biology and medicine. Adv Exp Med Biol 620:117-28.
49. Schwendener RA, Lagocki PA, Rahman YE. (1984). The effects of charge and size on the interaction of unilamellar liposomes with macrophages. Biochim Biophys Acta 772:93-101. (Pubitemid 14136820)
50. Sivan S, Schroeder A, Verberne G, et al. (2010). Liposomes act as effective biolubricants for friction reduction in human synovial joints. Langmuir 26:1107-16.
51. Trif M, Guillen C, Vaughan DM, et al. (2001). Liposomes as possible carriers for lactoferrin in the local treatment of inflammatory diseases. Exp Biol Med (Maywood) 226:559-64. (Pubitemid 32524502)
52. Trif M., Moisei M., Roseanu A., et al. (2007). Designing lipid nanostructures for local delivery of biologically active macromol-ecules. J Lipos Res 17:237-48. (Pubitemid 350133587)
53. Trif M, Moldovan L, Moisei M, et al. (2008). Liposomes-entrapped chondroitin sulphate: ultrastructural characterization and in vitro biocompatibility. Micron 39:1042-5.
54. Van den Hoven JM, van Tomme SR, Metselaar JM, et al. (2011). Liposomal drug formulations in the treatment of rheumatoid arthritis. Mol Pharm 8:1002-15.
55. Vanniasinghe AS, Bender V, Manolios N. (2009). The potential of liposomal drug delivery for the treatment of inflammatory arthritis. Semin Arthritis Rheum 39:182-96.
56. Wagner E. (2007). Programmed drug delivery: nanosystems for tumor targeting. Expert Opin Biol Ther 7:587-93. (Pubitemid 46707182)
57. 2 induces mitochondrial-mediated, MAPK-and caspase-independent growth inhibition and cytotoxicity in human gingival fibroblasts. Toxicol In Vitro 26:561-70.